# Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors

> **NCT07443020** · PHASE1 · RECRUITING · sponsor: **Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)** · enrollment: 10 (estimated)

## Conditions studied

- Malignant Pleural Effusion
- Malignant Mesothelioma
- Pleural Effusion, Malignant
- Metastasis to Pleura

## Interventions

- **BIOLOGICAL:** locally manufactured adoptive cellular therapy (ACT) product
- **DRUG:** Interleukin-2 (IL-2)

## Key facts

- **NCT ID:** NCT07443020
- **Lead sponsor:** Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2033-03
- **Final completion:** 2038-03
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-04-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07443020

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07443020, "Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07443020. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*